Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apyx Medical Corporation stock logo
APYX
Apyx Medical
$1.75
-8.4%
$1.99
$0.76
$2.73
$72.19M1.39116,511 shs117,927 shs
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
$4.87
+5.6%
$4.25
$2.03
$5.81
$80.84M1139,389 shs123,359 shs
TELA Bio, Inc. stock logo
TELA
TELA Bio
$1.86
+9.4%
$1.83
$0.86
$4.39
$67.24M0.9356,505 shs96,274 shs
Vaso Corporation stock logo
VASO
Vaso
$0.12
+0.2%
$0.13
$0.11
$0.32
$21.56M1.5838,508 shs41,127 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-8.38%-31.10%-18.60%+40.00%+28.68%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
+5.64%-1.81%+23.29%+37.18%-9.48%
TELA Bio, Inc. stock logo
TELA
TELA Bio
+9.41%-3.12%-2.62%+82.35%-58.20%
Vaso Corporation stock logo
VASO
Vaso
+0.49%-1.91%-2.23%-8.41%-54.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apyx Medical Corporation stock logo
APYX
Apyx Medical
1.1222 of 5 stars
0.03.00.04.20.01.70.6
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.3733 of 5 stars
0.02.00.00.01.50.80.6
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.3339 of 5 stars
3.44.00.00.00.61.70.6
Vaso Corporation stock logo
VASO
Vaso
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apyx Medical Corporation stock logo
APYX
Apyx Medical
2.67
Moderate BuyN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
0.00
N/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.75
Moderate Buy$7.25289.78% Upside
Vaso Corporation stock logo
VASO
Vaso
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apyx Medical Corporation stock logo
APYX
Apyx Medical
$48.10M1.37N/AN/A$0.38 per share4.61
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/A$2.40 per shareN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
$69.30M1.06N/AN/A$0.72 per share2.58
Vaso Corporation stock logo
VASO
Vaso
$86.77M0.25$0.01 per share12.14$0.16 per share0.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-$23.46M-$0.55N/AN/AN/A-42.37%-156.85%-31.92%8/7/2025 (Estimated)
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$21.82M-$1.18N/AN/AN/AN/A-54.13%-50.92%N/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$37.84M-$1.41N/AN/AN/A-61.00%-402.45%-62.73%8/11/2025 (Estimated)
Vaso Corporation stock logo
VASO
Vaso
$950KN/A0.00N/A1.20%3.93%1.37%8/12/2025 (Estimated)

Latest VASO, NVNO, APYX, and TELA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.18N/AN/AN/A$20.67 millionN/A
8/7/2025Q2 2025
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-$0.0933N/AN/AN/A$11.69 millionN/A
7/31/2025Q2 2025
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
-$0.28-$0.33-$0.05-$0.33N/AN/A
5/15/2025Q1 2025
Vaso Corporation stock logo
VASO
Vaso
N/A-$0.01N/A-$0.01N/A$19.46 million
5/8/2025Q1 2025
Apyx Medical Corporation stock logo
APYX
Apyx Medical
-$0.13-$0.10+$0.03-$0.10$9.39 million$9.43 million
5/8/2025Q1 2025
TELA Bio, Inc. stock logo
TELA
TELA Bio
-$0.21-$0.25-$0.04-$0.25$17.35 million$18.52 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apyx Medical Corporation stock logo
APYX
Apyx Medical
N/AN/AN/AN/AN/A
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/AN/AN/AN/AN/A
TELA Bio, Inc. stock logo
TELA
TELA Bio
N/AN/AN/AN/AN/A
Vaso Corporation stock logo
VASO
Vaso
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apyx Medical Corporation stock logo
APYX
Apyx Medical
3.21
5.45
4.64
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
N/A
23.77
23.77
TELA Bio, Inc. stock logo
TELA
TELA Bio
2.28
4.22
3.40
Vaso Corporation stock logo
VASO
Vaso
N/A
1.52
1.49

Institutional Ownership

CompanyInstitutional Ownership
Apyx Medical Corporation stock logo
APYX
Apyx Medical
55.33%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
34.71%
TELA Bio, Inc. stock logo
TELA
TELA Bio
94.35%
Vaso Corporation stock logo
VASO
Vaso
N/A

Insider Ownership

CompanyInsider Ownership
Apyx Medical Corporation stock logo
APYX
Apyx Medical
15.20%
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
16.00%
TELA Bio, Inc. stock logo
TELA
TELA Bio
4.70%
Vaso Corporation stock logo
VASO
Vaso
44.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apyx Medical Corporation stock logo
APYX
Apyx Medical
27037.79 million32.05 millionOptionable
enVVeno Medical Corporation stock logo
NVNO
enVVeno Medical
3017.54 million14.73 millionOptionable
TELA Bio, Inc. stock logo
TELA
TELA Bio
12039.56 million37.70 millionOptionable
Vaso Corporation stock logo
VASO
Vaso
260175.74 million97.54 millionNot Optionable

Recent News About These Companies

Corn in a Cup (Elote en Vaso)
Vaso Corporation Registered Shs
Top Analyst Reports for Apple, Philip Morris & Sony
Inflammation during menstrual cycle may trigger VOEs: Study

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apyx Medical stock logo

Apyx Medical NASDAQ:APYX

$1.75 -0.16 (-8.38%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.75 0.00 (0.00%)
As of 08/1/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

enVVeno Medical stock logo

enVVeno Medical NASDAQ:NVNO

$4.87 +0.26 (+5.64%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.88 +0.00 (+0.10%)
As of 08/1/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company's lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial.

TELA Bio stock logo

TELA Bio NASDAQ:TELA

$1.86 +0.16 (+9.41%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$1.86 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Vaso stock logo

Vaso OTCMKTS:VASO

$0.12 +0.00 (+0.24%)
As of 08/1/2025 02:53 PM Eastern

Vaso Corporation, together with its subsidiaries, operates in the healthcare equipment and information technology industries in the United States and internationally. The company operates through three segments: IT, Professional Sales Service, and Equipment. The IT segment primarily focuses on healthcare IT and managed network technology services. This segment offers managed diagnostic imaging applications, managed network infrastructure, managed network transport, and managed network security services. The Professional Sales Service segment principally focuses on the sale of healthcare capital equipment for General Electric Healthcare (GEHC) into the health provider middle market. Its offerings include GEHC diagnostic imaging equipment and ultrasound systems, GEHC service agreements, GEHC training, and GEHC and third-party financial services. The Equipment segment primarily focuses on the design, manufacture, sale, and service of proprietary medical devices and software. This segment offers Biox series Holter monitors and ambulatory blood pressure recorders; ARCS series analysis, reporting, and communication software for ECG and blood pressure signals, including cloud-based software and algorithm subscription services; MobiCare multi-parameter wireless vital-sign monitoring systems; and Enhanced External Counterpulsation therapy systems for non-invasive and outpatient treatment of ischemic heart disease. The company was formerly known as Vasomedical, Inc. and changed its name to Vaso Corporation in November 2016. Vaso Corporation was incorporated in 1987 and is headquartered in Plainview, New York.